Processa Pharmaceuticals, Inc. Sale of Stock, Consideration Received on Transaction
Processa Pharmaceuticals, Inc. (PCSA) reported Sale of Stock, Consideration Received on Transaction of $162.22 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-08-14
- Processa Pharmaceuticals, Inc. sale of stock, consideration received on transaction for the quarter ending 2026-06-30 was $162.22K.
- Processa Pharmaceuticals, Inc. sale of stock, consideration received on transaction for the quarter ending 2026-03-31 was $45.10K.
- Processa Pharmaceuticals, Inc. sale of stock, consideration received on transaction for the quarter ending 2023-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. sale of stock, consideration received on transaction for the quarter ending 2023-06-30 was $0.00.
| Period end | Sale of Stock, Consideration Received on Transaction 1 month | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 6 month | Sale of Stock, Consideration Received on Transaction 9 month |
|---|---|---|---|---|
| 2026-06-30 | $162.22K 10-Q · filed 2026-08-14 | $207.33K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $45.10K 10-Q · filed 2026-08-14 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $7.00M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $7.00M 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | $7.00M 10-Q · filed 2023-05-15 | |||
| 2015-03-31 | $88.00K 10-K · filed 2015-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |